赛诺医疗(688108) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥83,331,129.75, representing a year-on-year increase of 49.81%[3] - The net profit attributable to shareholders was -¥12,135,096.80 for the quarter, with a year-to-date loss of -¥41,746,244.78[3] - The basic earnings per share for Q3 2023 was -¥0.03, consistent with the diluted earnings per share[3] - Total operating revenue for the first three quarters of 2023 reached ¥244,617,074.10, a significant increase from ¥165,927,252.95 in the same period of 2022, representing a growth of approximately 47%[19] - Net profit for Q3 2023 was reported at -¥44,634,324.37, an improvement compared to -¥114,970,281.29 in Q3 2022, reflecting a reduction in losses by approximately 61%[21] - The company reported a total comprehensive loss of -¥43,763,727.53 for Q3 2023, compared to -¥111,411,535.72 in Q3 2022, showing an improvement of approximately 61%[21] - The basic earnings per share for Q3 2023 was -¥0.10, compared to -¥0.27 in Q3 2022, indicating a reduction in loss per share[21] Research and Development - Research and development expenses totaled ¥37,690,132.26, accounting for 45.23% of revenue, a decrease of 29.90 percentage points year-on-year[4] - Research and development expenses for the first three quarters of 2023 were ¥80,498,702.34, down from ¥112,714,356.64 in the same period of 2022, indicating a reduction of about 29%[19] Assets and Liabilities - Total assets increased by 3.50% to ¥1,104,935,849.17 compared to the end of the previous year[4] - The company's total liabilities increased to ¥245,316,444.16 in Q3 2023 from ¥180,130,924.62 in Q3 2022, marking an increase of about 36%[17] - The total equity attributable to shareholders decreased to ¥818,224,699.14 in Q3 2023 from ¥847,084,284.58 in Q3 2022, a decline of approximately 3.4%[17] - The company's total non-current liabilities rose to ¥98,861,235.07 in Q3 2023 from ¥47,947,441.79 in Q3 2022, an increase of approximately 106%[17] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥36,245,821.18[3] - Cash inflow from operating activities for the first three quarters of 2023 was 320,671,351.90 CNY, up from 189,322,213.56 CNY in the same period of 2022, representing an increase of approximately 69.3%[22] - The net cash flow from operating activities was 36,245,821.18 CNY, a significant improvement from -70,807,536.24 CNY in the previous year[22] - Cash inflow from financing activities was 63,000,000.00 CNY, up from 30,000,000.00 CNY in the previous year[23] - The net cash flow from financing activities increased to 44,657,593.34 CNY, compared to 22,662,299.20 CNY in the same period last year[23] Inventory and Receivables - Current assets totaled RMB 349,791,807.62, slightly down from RMB 354,901,057.55 at the end of 2022[15] - Accounts receivable decreased to RMB 14,934,059.96 from RMB 20,281,372.41[14] - Inventory increased to RMB 107,461,754.87 from RMB 98,125,844.24[15] Government Support - Government subsidies contributed to the increase in net profit attributable to shareholders, which saw a substantial year-on-year growth[8] Shareholder Information - The company reported a total of 9,806 common shareholders at the end of the reporting period[10]